FDA opposition to legislation that would loosen conflict of interest rules does not seem to deter congressional efforts to include the requirement in the Prescription Drug User Fee Act reauthorization.
A bill would not help, Commissioner Margaret Hamburg reiterated during a Feb
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?